Related Experiment Video
Updated: May 30, 2025
05:55
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
6.7K
Prohibitins in infection: potential therapeutic targets
Nuo Chen1, Xiaolan Liu1, Lulu Wang1
1Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, P. R. China.
Future Microbiology
|January 30, 2025
Summary
Prohibitins (PHB1 and PHB2) regulate viral, bacterial, and fungal infections. Targeting these proteins offers new therapeutic strategies for infectious diseases.
Area of Science:
- Molecular Biology
- Immunology
- Microbiology
Background:
- Prohibitins (PHB1, PHB2) are conserved proteins found in mitochondria, nucleus, and cell membranes.
- They are crucial for mitochondrial biogenesis, apoptosis, and immune responses.
- PHB1 and PHB2 participate in pathogen infection processes, acting individually or as a complex.
Purpose of the Study:
- To review the regulatory roles of PHB1 and PHB2 in various microbial infections.
- To provide insights into the mechanisms of PHB-mediated infection regulation.
- To highlight PHB proteins as potential therapeutic targets for infectious diseases.
Main Methods:
- Literature review of studies on Prohibitins in microbial infections.
- Analysis of PHB1 and PHB2 functions in viral, bacterial, parasitic, and fungal infections.
- Synthesis of current understanding and future perspectives.
Main Results:
- PHB1 and PHB2 play significant roles in host defense against a range of pathogens.
- Their functions are diverse, impacting pathogen entry, replication, and host immune response.
- Evidence suggests PHB proteins are involved in regulating the severity and outcome of infections.
Conclusions:
- PHB proteins are key regulators in the host-pathogen interaction.
- Understanding PHB mechanisms offers novel therapeutic avenues for infectious diseases.
- Targeting PHB proteins presents a promising strategy for developing new anti-infective treatments.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
8.6K
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
8.5K
Related Concept Videos
01:23Antimicrobial Proteins
881
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
881
01:30Enzyme Inhibition
77.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.8K
01:52Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
01:26Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
01:23Types of RNA
63.1K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
63.1K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K